Nadia Mensali

  • Postdoc; PhD
  • +47 22 78 23 19




2008/- :           Ph.D. in Tumour Immunology, Faculty of Medicine, University of Oslo, Norway  

2003/2004:      Master in Clinic and Experimental Citometry, University of Urbino, Italy

1995/2001:      Laurea in Biology, section Physiopathology, University of Urbino, Italy



Research interests/projects


Adoptive T-cell therapy

  • pre-clinical validation of TCRs for therapeutic use
  • pre-clinical validation of universal killer T cells
  • development of novel technologies to improve cell-based therapy


Antigen presentation

  • validation of novel methods to improve antigen presentation in the context of vaccination
  • invariant chain as a tool for patient vaccination


Work experiences


2016/present:  Postdoc Fellow, Dept of Cellular Therapy, OUS Radiumhospitalet, Oslo, Norway

2014/2015:      Researcher, Dept of Biosciences, University of Oslo, Oslo, Norway

2008/2014:     PhD Student, Department of Immunology, Institute for Cancer Research, OUS-Radiumhospitalet, Oslo, Norway

2007/2008:     Laboratory Research Analyst II, Duke Center for AIDS Research (CFAR) at the Department of Surgery, Duke University Medical Center, Durham, NC, US

2005/2007:     Laboratory Research Analyst I, Duke Center for AIDS Research (CFAR) at the Department of Surgery, Duke University Medical Center, Durham, NC, US

2002/2004:     Biologist, Laboratory of Onco-Hematology, Flow Cytometry Laboratory, at the Center for Bone Marrow Transplant, “San Salvatore” Hospital, Pesaro, Italy.

1999/2001:      Internship, Center of Cytometry and Cytomorphology, University of Urbino, Italy


Publications 2019

Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S (2019)
NK cells specifically TCR-dressed to kill cancer cells
EBioMedicine, 40, 106-117
DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853

Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S (2019)
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
Oncoimmunology, 8 (3), 1558663
DOI 10.1080/2162402X.2018.1558663, PubMed 30723591

Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2019)
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732

Publications 2017

Inderberg EM, Mensali N, Oksvold MP, Fallang LE, Fåne A, Skorstad G, Stenvik GE, Progida C, Bakke O, Kvalheim G, Myklebust JH, Wälchli S (2017)
Human c-SRC kinase (CSK) overexpression makes T cells dummy
Cancer Immunol Immunother, 67 (4), 525-536
DOI 10.1007/s00262-017-2105-9, PubMed 29248956

Publications 2016

Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, Fallang LE, Kolstad A, Uckert W, Malmberg KJ, Wälchli S, Olweus J (2016)
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA
Oncoimmunology, 5 (5), e1138199
DOI 10.1080/2162402X.2016.1138199, PubMed 27467957

Publications 2015

Tadesse FG, Mensali N, Fallang LE, Walseng E, Yang W, Olweus J, Wälchli S (2015)
Unpredicted phenotypes of two mutants of the TcR DMF5
J Immunol Methods, 425, 37-44
DOI 10.1016/j.jim.2015.06.006, PubMed 26079729

Publications 2011

Abrahamsen IW, Kjellevoll S, Greve-Isdahl M, Mensali N, Wälchli S, Kumari S, Loland BF, Egeland T, Kolstad A, Olweus J (2011)
T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells
Int J Cancer, 130 (8), 1821-32
DOI 10.1002/ijc.26209, PubMed 21630262

Publications 2008

Gasper-Smith N, Crossman DM, Whitesides JF, Mensali N, Ottinger JS, Plonk SG, Moody MA, Ferrari G, Weinhold KJ, Miller SE, Reich CF, Qin L, Self SG, Shaw GM, Denny TN, Jones LE, Pisetsky DS, Haynes BF (2008)
Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design
J Virol, 82 (15), 7700-10
DOI 10.1128/JVI.00605-08, PubMed 18508902

Page visits: 2665